Study investigating the effect of irsogladine maleate on PPI-resistant GERD

Study investigating the effect of irsogladine maleate on PPI-resistant GERD - irsogladine on GERD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003013

Enrollment

Registered

2010-02-01

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GERD

Interventions

co-administration of irsogladine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients with sGERD whose mean QOLRAD-J score are less than 5

Exclusion criteria

Exclusion criteria: Cases taking H2RA,mucosa defencing agents,mucoprotective agents. Cases who took PPI in the recent 2 weeks. Cases taking NSAIDs,salicylate, antimuscarinic agents,prokinetics, PG. Cases whose inclusion is considered to be inappropriate by the attending physicians.

Design outcomes

Primary

Measure	Time frame
clinical symptoms and QOL evaluated by questionaires.	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026